| Name | Title | Contact Details |
|---|---|---|
Garry Pairaudeau |
Chief Technology Officer | Profile |
Eileen Jennings-Brown |
Chief Information Officer | Profile |
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.
Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.
ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.